ALUMIS INC

ALMS03 Dec 2024
Healthcare
$8.88
-0.11 (-10.80%)
Lowest Today
$8.22
Highest Today
$8.93
Today’s Open
$8.88
Prev. Close
$9.26
52 Week High
$16
52 Week Low
$8.23
To Invest in ALUMIS INC

ALUMIS INC

Healthcare
ALMS03 Dec 2024
-0.11 (-10.80%)
1M
3M
6M
1Y
5Y
Low
$8.22
Day’s Range
High
$8.93
8.22
52 Week Low
$8.22
52-Week Range
52 Week High
$16
8.22
1 Day
-
1 Week
-2.52%
1 month return
-17.54%
3 month return
-27.08%
6 month return
-27.76%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
630.53 mln
PB Ratio
0
PE Ratio
0
Enterprise Value
452.58 mln
Total Assets
89.61 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Organisation
ALUMIS INC
Employees
107
Industry
Biotechnology
CEO
Mr. Martin  Babler Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities